Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sawai to Raise Awareness for Launch of Alcoholism Therapy App HAUDY
August 28, 2025
- Meiji Breaks Ground on “Dual-Use” Plant for Antibiotics and Vaccines
August 28, 2025
- Nihon Chouzai Shuts Down FINDAT Formulary Biz amid Tepid Demand
August 28, 2025
- Amicus’ Pompe Disease Drugs Hit Japan Market
August 28, 2025
- LP.8.1-Tailored Nuvaxovid COVID Jab Approved in Japan: Takeda
August 28, 2025
- Kringle, Keio Pair Up on HGF Therapy for Peripheral Nerve Injury
August 27, 2025
- ASKA Presses Dalton for Transparency on 30% Stake Plan
August 26, 2025
- Meiji Revives Penicillin Raw Material Production in Japan after 31 Years, Races to Pass Down Know-How
August 26, 2025
- Nippon Kayaku to Set Up Singapore-Based JV to License Drugs in Asia
August 26, 2025
- Dayvigo, Jardiance Heavily Promoted in July: Intage
August 26, 2025
- Japan Approves Roche Diagnostics Test for HER2 Ultralow Breast Cancer
August 26, 2025
- Daiichi Sankyo’s TROP2 ADC Datroway Approved in China
August 26, 2025
- Austria, Germany Become First EU Markets to Launch Leqembi
August 26, 2025
- Astellas CFO Outlines Cost Cuts, Licensing Push as Xtandi Nears Patent Cliff
August 25, 2025
- Meiji’s Rezurock Approved in Thailand
August 25, 2025
- Linepharma Japan Eyes Ophthalmology as Second Pillar to Women’s Health
August 22, 2025
- Sanofi Begins Japan PII for Type 1 Diabetes Med Teplizumab
August 22, 2025
- Meiji Group Launches PII Trial of Dengue Vaccine in Thailand
August 22, 2025
- Itochu Launches J-STEP to Help Overseas Drug Makers Tackle Japan’s “Drug Loss”
August 21, 2025
- ASKA, MICIN Team Up to Develop IBS Treatment App
August 21, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…